Neuropsychiatric Sequelae of Traumatic Brain Injury
The authors review the psychiatric disturbances associated with traumatic brain injury. Theyhighlight the close link between traumatic brain injury and psychiatry and provide an overviewof the epidemiology, risk factors, classification, and mechanisms of traumatic brain injury. Theydescribe various neuropsychiatric sequelae, and the respective treatments are outlined with em-phasis on a multidisciplinary approach.
[Note: The following article is the fifth in a special neu-
500,000 will probably require hospitalization, and about
ropsychiatry series edited by Dr. Constantine Lyketsos. The
80,000 will suffer from some level of chronic disability.1 Men
first four articles appeared in the January–February 2000
are injured twice as frequently as women, with the risk of
fatal head injury being four times greater. The incidence ofhead injury increases to peak from ages 15 to 25, thereafter
TraumaisacommoncauseofbraininjuryintheUnited fallingoff,onlytoriseagaininlateryears.2Inpersonsunder
States and is a significant public health problem.1
45 years of age, TBI is the leading cause of death and dis-
Traumatic brain injury (TBI) can result in a variety of neu-
ability, with an overall mortality rate of 25 per 100,000. Motor
ropsychiatric disturbances ranging from subtle deficits to
vehicle accidents are the most common cause of head injury,
severe intellectual and emotional disturbances. In rare
accounting for more than 50%, followed by falls (21%), vi-
cases, it results in chronic vegetative states. The neuropsy-
olence (12%), and injuries from sports or recreational activ-
chiatric disturbances associated with TBI include cognitive
ities (10%).3 Health costs from TBI are estimated to be on
impairments, mood disorders, anxiety disorder, psychosis,
This article will provide an overview of the common
Risk Factors for Neuropsychiatric Disorders
neuropsychiatric sequelae of TBI along with a guide to theassessment and treatment of these conditions. The primarygoal of this review is to demonstrate the link between psy-
The major risk factors for neuropsychiatric distur-
chiatry and TBI. We will summarize the epidemiology, risk
bances after TBI include increasing age, arteriosclerosis,
factors, classification, and mechanism of brain injury after
and alcoholism. These all delay the reparative process
TBI. Next, a description of the various neuropsychiatric
within the central nervous system.5 Premorbid personality
disorders associated with TBI will be provided. Finally, a
also a plays a significant role in the process of rehabilita-
brief discussion of pharmacological treatment in TBI will
tion, as was pointed out by Symonds: “The response to
be outlined, followed by concluding remarks.
head injury depends on the kind of head that was injured.”6
Received and accepted September 2, 1999. From the Neuropsychiatryand Memory Group, Department of Psychiatry and Behavioral Sciences,
School of Medicine, The Johns Hopkins University, Baltimore, Maryland. Address reprint requests to Dr. Rao, Osler 320, The Johns Hopkins Hos-
The annual incidence of head trauma in the United States
pital, Baltimore, MD 21287. email: [email protected]
is approximately 2 million per year.1 Of these patients,
Copyright ᭧ 2000 The Academy of Psychosomatic Medicine.
Similarly, factors such as marital discord, poor interper-
oxia, anemia, metabolic abnormalities, hydrocephalus, in-
sonal relationships, problems at work, or financial insta-
tracranial hypertension, fat embolism, and subarachnoid
bility are important contributors to the neuropsychiatric
hemorrhage. Other delayed effects include release of ex-
citatory amino acids, oxidative free-radical production, re-lease of arachidonic acid metabolites, and disruption of
neurotransmitters like monoamines and serotonin.15–17
Head injury can be classified along several lines. The
most common classification is based on physical trauma:open vs. closed head injury, depending on whether or notthe skull has been breached.
The neuropsychiatric disturbances associated with TBI are
Another important classification system depends on
numerous. They are generally observed to be disorders of
the severity of initial impairment, combining the initial
mood, cognition, or behavior. Cognitive deficit has been
Glasgow Coma Scale (GCS), the duration of loss of con-
variously classified as delirium,14 dementia due to head
sciousness (LOC), and the duration of posttraumatic am-
trauma,2 amnestic disorder due to head trauma,2 or intel-
nesia (PTA).9 A GCS of 13–15, LOC of less than 30 min-
lectual impairment,18 depending on the variety of symp-
utes, and/or PTA of less than 1 hour is classified as mild
toms and their time of onset and resolution. The behavioral
TBI. People with moderate TBI have a GCS of 9–12, LOC
problems associated with TBI have been the most difficult
of 1–24 hours, and/or PTA of 30 minutes to 24 hours. A
to classify. The signs and symptoms of the frontal and tem-
GCS of 8 or less, LOC of more 24 hours, and/or PTA of
poral lobe damage have been variously classified as frontal
more than 1 day is classified as severe TBI.9 Some studies
and temporal lobe syndromes,9 aggressive disorders,19 and
have used only the GCS to classify the severity,10 whereas
others have used LOC and/or PTA.11 The prognosis of
In our opinion, these terms are too restrictive to describe
moderate and severe TBI is fairly well correlated with these
the complex clinical manifestations of diffuse brain damage.
characteristics, but the relationship is not as clear with
Organic Personality Syndrome or Personality Changes Due
milder forms of TBI, which falls into a less well-defined
to Head Trauma are also misnomers, as there are no pro-
spective studies to document that these symptoms are an ex-aggeration of premorbid personality. The DSM-IV classifi-
cation of the neuropsychiatric sequelae of TBI is alsoinadequate. Except for “dementia due to head trauma,” all
TBI is the result of mechanical forces applied to the
other disorders are classified as “disorder due to general-
skull and transmitted to the brain. This may lead to focal
medical condition.” The term post-concussion syndrome
and/or diffuse brain damage. Focal lesions often result
(PCS), frequently noted in the literature, is also vague and
from a direct blow to the head and include brain laceration,
nondescriptive. It is also a misnomer because it can be seen
contusion, intracerebral hemorrhage, subarachnoid or sub-
in anyone with TBI, with or without a “concussion.”
dural hemorrhage, and ischemic infarct. Contusion occurs
We propose a classification of the neuropsychiatric se-
directly beneath or contralateral to the site of impact, com-
quelae of TBI according to their phenomenology as de-
monly referred to as coup and contre-coup injury.12 It is
scribed in Table 1. We prefer the term “behavioral dyscon-
most common in the orbital–frontal area and the temporal
trol disorder, major variant” to describe a specific
tips, where acceleration/deceleration forces cause the brain
syndrome of mood, cognitive, and behavioral disturbances
to impact on the bony protuberances of the skull.13
following head injury. The term “behavioral dyscontrol
Diffuse brain injury also results from the differential
disorder, minor variant” is preferred to describe what is
motion of the brain within the skull, causing a shearing and
known as “post-concussion syndrome.” We believe that
stretching of the axons.3 This can produce a wide spectrum
both these disorders have the same etiopathogenesis; that
of injuries, ranging from brief physiological disruption to
is, diffuse brain damage, with predominance of frontal and
widespread axonal tearing, called diffuse axonal injury
temporal lobe lesions, as they are more likely to be injured.
(DAI).14 In addition to brain damage occurring at the time
The two disorders probably differ only in the severity of
of the impact, secondary damage from several processes
their symptoms—major variant being more severe. The
may occur during the recovery period. These include hyp-
major variant has predominantly behavior symptoms, com-
pared with the minor variant, which has more somatic
come depends on a number of factors, such as degree of
symptoms. What follows is a discussion of these disorders.
diffuse axonal injury, duration of LOC and PTA, clinicalevidence of brain stem dysfunction at the time of injury,
and presence and size of focal hemispheric injury.
Treatment is multidisciplinary and includes pharma-
TBI is associated with a plethora of cognitive deficits,
cotherapy, physical therapy, occupational therapy, recrea-
some of which are more common than others. They include
tion therapy, speech therapy, and vocational rehabilitation.
impairment of arousal, attention, concentration, memory,
Cognitive rehabilitation is also important, especially during
language, and executive function. Loss of memory may be
the first 6 months after injury, and involves techniques to
for both verbal and nonverbal skills. Disturbances of ex-
retrain the patient in specific domains by providing a series
ecutive functioning include poor planning, organizing, se-
of mental stimuli, tests, and activities.22 Dopaminergics23
quencing, and set-shifting, with impaired judgment and im-
or psychostimulants may improve deficits of arousal, poor
attention, concentration, and memory. Numerous case re-
Researchers have suggested that cognitive deficits can
ports are available on the efficacy of dopaminergics in
be divided into four groups according to when they occur
treating cognitive symptoms.24–26 Cholinergic agents such
in relation to the phases of the TBI.20,21 The first is the period
as those developed to treat dementia are also showing
of loss of consciousness or coma, which occurs soon after
injury. The second phase is characterized by a mixture ofcognitive and behavioral abnormalities, such as agitation,
confusion, disorientation, and alteration in psychomotor ac-tivity. This period is associated with inability to recall
Mood disorders associated with TBI have been re-
events, sequence time, and learn new information. The first
ported in the medical literature for a number of years.
two phases, which last anywhere from a few days to 1 month
Adolf Meyer, in 1904, referred to these symptoms as “trau-
after injury, are a form of posttraumatic delirium.14 What
matic insanities,” and proposed that there might be an as-
follows is a 6–12 month period of rapid recovery of cog-
sociation between these symptoms and brain lesions.29 De-
nitive function, followed by plateauing of recovery over 12–
pression and mania are common after TBI.
24 months subsequent to the injury. The fourth phase is
Major depression occurs in approximately 25% of pa-
characterized by permanent cognitive sequelae, and includes
tients with TBI.30,31 Feelings of loss, demoralization, and dis-
problems with speed of information-processing, attention
couragement seen soon after injury are often followed by
and vigilance, short- and long-term memory deficits, verbal
symptoms of persistent dysphoria. Fatigue, irritability, sui-
and nonverbal deficits, and problems with executive func-
cidal thoughts, anhedonia, disinterest, and insomnia are seen
tions and mental inflexibility. This phase has also been de-
in a substantial number of patients 6–24 months or even
scribed as “dementia due to head trauma.”
longer after TBI.32,33 Psychological impairments in excess of
The cognitive deficits are caused by the cumulative
the severity of injury and poor cooperation with rehabilitation
effects of focal and diffuse brain damage.14 Cognitive out-
are strong indicators of a persistent depressive disorder.9Clinical and research studies have also shown that poor pre-morbid level of functioning and past history of psychiatric
Neuropsychiatric sequelae of traumatic brain injury (TBI)
illness are major risk factors for depression.30 The mechanismof depression following head injury is probably due to dis-
ruption of biogenic amine-containing neurons as they pass
through the basal ganglia or frontal-subcortical white mat-
ter.34 The presence of left dorsolateral frontal and left basal
ganglia lesions is associated with an increased probability of
The treatment of depression secondary to TBI is very
similar to the treatment of major depressive disorder. It
includes antidepressants, psychostimulants, and electro-
convulsive therapy (ECT). The choice of medications must
be influenced by their side-effect profile. Agents such as
serotonin-specific reuptake inhibitors (SSRIs) are safe and
tant as pharmacotherapy in the treatment of anxiety dis-
well tolerated.35 Drugs with anticholinergic effects in gen-
eral should be avoided. Psychostimulants36,37 and even thedopaminergics can be helpful in these cases, as they have
an antidepressant effect. ECT is a highly effective mode oftreatment for TBI patients refractory to antidepressants.38It is important to remember that in TBI patients, mood
Psychotic symptoms are not uncommon in TBI pa-
disorders are commonly accompanied by problems in the
tients. A review of the literature by Davison and Bagley51
other categories—cognitive, behavioral, and somatic.
revealed that 0.7%–9.8 % of patients with TBI develop
Treatment should attempt to address as many areas as pos-
schizophrenia-like psychosis. Most of these patients do not
sible, and at the least, not worsen any specific area.
have a family history of schizophrenia. Other studies have
Mania after TBI is less common than depression but
shown that the incidence of head injury pre-dating psy-
much more common than in the general population. It is
chotic symptoms in a population of patients with schizo-
seen in about 9% of patients.39 Changes in mood, sleep,
phrenia is about 15%.52 Psychotic symptoms following
and activation may manifest as irritability, euphoria, in-
TBI often manifest as frank delusions, hallucinations, and
somnia, agitation, aggression, impulsivity, and even violent
illogical thinking. They may also be associated with symp-
behavior.40 Positive family history of affective disorder and
toms of agitation, ideas of reference, grimacing, silly gig-
subcortical atrophy prior to TBI are added risk factors.41
gling, expression of odd ideas, regression, and impulsive
Mania is often seen in patients with right-hemispheric lim-
aggressiveness.53,54 The psychotic features may be acute or
chronic, transient or persistent, and may or may not be
Treatment with anticonvulsants such as carbamaze-
pine or valproate may be more effective than lithium,
Both right55 and left hemispheres56 have been impli-
which is not specific to the neuropathology of TBI and may
cated in the genesis of psychotic symptoms. It is important
worsen cognitive impairment.9 Other than this, there is lit-
to remember that psychosis is a symptom, not a diagnosis
tle empirical knowledge about the treatment of mania fol-
A rational approach based on our knowledge of the
neuropathology of TBI must be applied when choosingtreatment options. For instance, when there is a suggestion
of left-temporal involvement, there may be benefit fromthe use of an anticonvulsant. Delusional-type symptoms
Anxiety disorders are common in patients with TBI
that seem more related to cognitive and behavioral impair-
and range in frequency from 11%–70%.42,43 All variants
ments from frontal lobe dysfunction can benefit from do-
of anxiety disorders are seen, including generalized anxiety
paminergics. Neuroleptics, if administered, should be
disorder, panic disorder, phobic disorders, posttraumatic
given in low doses, as animal studies have shown impaired
stress disorder, and obsessive–compulsive disorder. TBI
patients often experience generalized “free-floating” anxi-ety associated with persistent worry, tension, and fearful-
ness.44 Increased activity of the aminergic system and de-creased activity of the GABA inhibitory network is theproposed mechanism for the clinical manifestation of anxi-
Ten percent of patients tend to have apathy without
ety.45 Right-hemispheric lesions are more often associated
depression, and 60% have some degree of apathy and de-
with anxiety disorder than left-sided lesions.46
pression following TBI.58 Apathy refers to a syndrome of
Anecdotal evidence suggests that antidepressants such
disinterest, disengagement, inertia, lack of motivation, and
as SSRIs, opioid antagonists such as naltrexone,47 and bus-
absence of emotional responsivity. The negative affect and
pirone48 are promising in the treatment of anxiety disor-
cognitive deficits seen in patients with depression are not
ders. Benzodiazipines49 and antipsychotics50 should be
seen in patients with apathy. Apathy may be secondary to
avoided because they cause memory impairment, disinhi-
damage of the mesial frontal lobe.59 It often responds well
bition, and delayed neuronal recovery.
to either psychostimulants, dextroamphetamine, amanta-
Behavioral therapy and psychotherapy are as impor-
ing longer than 1 year.68,69 The underlying pathogenesis isthought to be diffuse axonal injury from acceleration and
deceleration forces. Interestingly, however, in some pa-
nitive, and behavioral manifestations is seen in a number
tients, the neurologic exam, neuropsychological testing,
of patients after TBI.61 This occurs in both the acute and
and neuroimaging studies have all been normal. Case re-
chronic stages after TBI and in patients with mild, mod-
ports of positron emission tomography (PET ) and single-
erate, and severe injury. Its prevalence is about 5%–70%.19
photon emission computerized tomography (SPECT) stud-
Because the major feature of the syndrome is dyscontrol
ies are available that have shown focal abnormalities of
of emotion, behavior, and cognition, we prefer the term
glucose uptake and regional cerebral blood flow, respec-
behavior dyscontrol disorder, major variant to define the
tively.70,71 As far as we know, case-controlled studies of
large series of patients are not available. Functional mag-
Behavior dyscontrol disorder may be due to the effects
netic resonance imaging (fMRI) studies might be able to
of both focal and diffuse brain injury that results in a dis-
shed light on this controversial syndrome. The perplexing
ruption of neuronal network, creating lapses in cognitive
question is whether PCS is really a separate entity with
functioning and coarsening of behavior. Focal damage to
specific features or is merely a milder version of the be-
the orbital–frontal area causes disinhibition, and injury to
the dorsal convexity of the frontal lobe causes dysexecutive
The management of this disorder should be practical
symptoms.59 Damage to the temporal lobes causes emo-
and holistic. Education and support of patients and family
members should be associated with supportive and behav-
A multidisciplinary approach should be maintained in
ioral psychotherapy, occupational and vocational interven-
treating these patients. They would benefit from a combi-
tion, and social skills training. If the patient is experiencing
nation of environmental modification strategies;62 behav-
significant cognitive or emotional difficulties, he or she
ioral therapy, including positive and negative reinforce-
should be evaluated for an affective or anxiety disorder and
ment; vocational training;63 supportive psychotherapy; and
family therapy.64 Pharmacotherapy for behavior dyscontroldisorder would include use of dopaminergic agents, psy-chostimulants, opioid antagonists, SSRIs, high-dose beta-
blockers, buspirone, trazodone, and anticonvulsants.60,65
Behavior dyscontrol disorder, minor var-
TBI patients may present with a variety of other symp-
iant, or post-concussion syndrome (PCS), is the most com-
toms, such as sleep disturbances or headaches. Careful
monly diagnosed entity following TBI. The syndrome is
evaluation of these patients should be done to ascertain if
poorly defined and has been a source of controversy for a
they are just isolated symptoms or if they are part of a
number of years. It refers to a cluster of signs and symp-
syndrome. Treatment should be aimed at a specific disorder
toms that often follows mild TBI but can occur with injury
of any severity.66 LOC is not necessary for its develop-ment.9 The symptoms of PCS can be broadly divided into
Behavior dyscontrol disorder, minor variant
somatic, cognitive, and mood symptoms (Table 3).9
Cognition Somatic Symptoms
Most patients recover within 3–6 months after injury.67
However, about 15% of patients will have symptoms last-
Behavior dyscontrol disorder, major variant Cognition Behavior
injury.17 The frontal lobes are especially rich in dopamine,
and their frequent involvement in TBI is associated withdecreased dopamine activity. Amantadine, bromocriptine,
Treatment of neuropsychiatric sequelae of TBI is compli-
and levodopa are commonly used dopaminergic agents.
cated. It includes pharmacological therapy and rehabilita-
Amantadine was first used in the 1960s for treatment
tive interventions, which are equally important. Rehabili-
of influenza and was later found to have antiparkinsonian
tation should begin on the day of the injury and continue
actions.73 It enhances release of dopamine, inhibits reup-
until the patient is stable or has reached his or her pre-
take, and increases activity at the postsynaptic receptors.74
injury baseline. Rehabilitation is multifaceted. It includes
Also, it is an N-methyl-D-aspartate (NMDA) glutamate re-
cognitive rehabilitation, behavioral treatment, social skills
ceptor antagonist, and this property might protect neuronal
training, vocational training, individual therapy, group
cells against excitotoxicity.74 Side effects of amantadine
therapy, and family therapy. In this review, we will not be
include confusion, hallucinations, edema, and hypotension.
discussing the extensive array of different rehabilitative
Optimal doses are found to be between 50 mg/day and 400
measures; we will focus our attention only on the discus-
mg/day. Case reports have shown that amantadine is useful
sion of psychopharmacology in TBI patients. The overview
in the treatment of mutism, impulsivity, and aggression,
certainly does not encompass all the drugs used in brain-
and helpful for information-processing, apathy, and inat-
injured patients, but includes only the most commonly ad-
tention.74 Gualtieri60 studied the effects of amantadine in
30 severely impaired TBI patients 2–144 months after in-
The literature review reveals that there have been very
jury. Sixty-three percent were noted to have improvement
few randomized controlled studies of neuropsychiatric se-
in symptoms of agitation, distractibility, emotional lability,
quelae of TBI. Most reports in literature are either anecdotal
reports or uncontrolled small-series case studies. In general,
Levadopa and bromocriptine are both dopamine ago-
TBI patients are very sensitive to medications; hence, treat-
nists. They have been studied in small, uncontrolled case
ment should be initiated at low doses with gradual increase.
studies and have been found to be effective in the treatment
Careful and close monitoring of patients during treatment is
of mood, cognition, and behavior.75,76 Lal et al.75 studied
mandatory. The commonly used medications in brain-in-
the effect of L-dopa/carbidopa in 12 moderate or severe
jured patients are psychostimulants, dopaminergic agents,
TBI patients and found functional cognitive and behavioral
and antidepressants, and other drugs, such as opioid antag-
improvement. Common side effects of these medications
onists, beta-blockers, and anticonvulsants.
include nausea, psychosis, and sedation. The dose of L-
dopa/carbidopa varies from 10/100 mg to 25/100 mg qid. Bromocriptine is initiated at 2.5 mg/day and gradually in-
Methylphenidate and dextroamphetamine are the com-
monly used psychostimulants. They act by increasing cat-echolamine activity by blocking the reuptake of norepi-
nephrine and dopamine.65 Side effects include paranoia,dysphoria, agitation, and irritability. Methylphenidate is
SSRIs are useful in the treatment of depression, mood
usually initiated at 5 mg bid and dextroamphetamine at 2.5
lability, and impulsivity.9 However, no placebo-controlled,
mg bid. The maximum dose of both drugs is 60 mg/day.
double-blind case series is available to demonstrate the ef-
Anecdotal reports have demonstrated the efficacy of
ficacy of these medications. Tricyclics and monoamine ox-
psychostimulants in the treatment of inattention, distracti-
idase inhibitors are generally not preferred in the treatment
bility, disorganization, hyperactivity, impulsivity, hypo-
of TBI patients because of their anticholinergic side effects
arousal, apathy, and hypersomnia.24,37,72 One double-blind,
and drug–food interactions, respectively. Saran77 con-
placebo-controlled cross-over study of methylphenidate in
ducted a cross-over study of phenelzine and amitriptyline
15 TBI patients showed improvement in mood and cog-
in patients with minor brain injury and found no response.
Studies have shown that trazodone is useful for agitationand sleep.78 For information about and dosage of these
drugs, the reader is advised to refer to the psychopharma-
TBI is frequently associated with disturbances of do-
cology chapter in Neuropsychiatry of Traumatic Brain In-
pamine transmission, which persists for many years after
treating self-injurious behavior.82 A study on three bulimicTBI patients83 reported its efficacy.
The role of anticonvulsants in the treatment of neu-
Buspirone, a selective serotonin antagonist is useful in
ropsychiatric sequelae of TBI are multiple. They are used
the treatment of anxiety disorders and aggression in doses
to treat seizure disorder, mood lability, mania, impulsivity,
aggression, and rage.79,80 Carbamazepine and valproic acid
Similarly, beta-blockers, such as propranolol, have
are most commonly used and found to be equally benefi-
also been used to treat aggression and violent behavior.85
cial. No large-scale controlled studies are available to dem-onstrate the efficacy of these drugs. Phenytoin and barbi-
Patients with traumatic brain injury are often referred to as
performance81 and, hence, are not recommended. For in-
“the walking wounded,” because a number of them have
formation about and dosage of these drugs, the reader is
persistent neuropsychiatric sequelae. Even though they ap-
advised to refer to the psychopharmacology chapter in
pear physically “normal,” they are disabled personally, so-
Neuropsychiatry of Traumatic Brain Injury.65
cially, and occupationally. Ideally, treatment of these pa-tient should involve a multidisciplinary approach, with the
neuropsychiatrist working in close collaboration with thepatient, family, neurologist/neurosurgeon, physiatrist, so-
Studies have shown that naltrexone, an opioid antag-
cial worker, and the staff of community groups such as the
onist, in doses of 50 mg–100 mg/day may be useful in
local chapter of the brain injury association. References
1. Frankowski RF: Descriptive epidemiologic studies of head injury
13. Gennarelli TA: Cerebral concussion and diffuse brain injuries, in
in the United States: 1974–1984. Adv Psychosom Med 1986;
Head Injury, Vol 2. Edited by Cooper PK. Baltimore, MD, Williams
2. Capruso DX, Levin HS: Neuropsychiatric aspects of head trauma,
14. Kwentus JA, Hart RP, Peck ET, et al: Psychiatric complications of
in Comprehensive Textbook of Psychiatry, Vol 1. Edited by Kaplan
closed head trauma. Psychosomatics 1985; 26:8–15
HI, Saddock BJ. Baltimore, MD, Williams & Wilkins, 1995, pp
15. Palmer AM, Marion DW, Botscheller ML, et al: Traumatic brain
injury-induced excitotoxicity assessed in a controlled cortical im-
3. McAllister TW: Neuropsychiatric sequelae of head injuries. Psy-
pact model. J Neurochem 1993; 61:2015–2024
16. Hammill RW, Woolf PD, McDonald JV, et al: Catecholamines pre-
4. Max W, Mackenzie E, Rice D: Head injuries: cost and conse-
dict outcome in traumatic brain injury. Ann Neurol 1987; 21:438–
quences. J Head Trauma Rehabil 1991; 6:76–91
5. Lishman WA: Physiogenesis and psychogenesis in the post-
17. Vecht CJ, van Woekom TCAM, Teelken AW, et al: Homovanillic
concussional syndrome. Br J Psychiatry 1988; 153:460–469
acid and 5-hydroxyindole acetic acid cerebrospinal fluid levels.
6. Symonds CP: Mental disorder following head injury. Proceedings
of the Royal Society of Medicine 1937; 30:1081–1092
18. Lishman WA: The psychiatric sequelae of head injury: a review.
7. Whitlock FA, Stoll JK, Rekhdahl RJ: Crisis, life events, and acci-
dents. Aust N Z J Psychiatry 1977; 11:127–132
19. Silver JM, Yudofsky SC: Aggressive disorder, in Neuropsychiatry
8. Selzer ML, Rogers JE, Kern S: Fatal accidents: the role of psycho-
of Traumatic Brain Injury. Edited by Silver JM, Yudofsky SC,
pathology social stress, and acute disturbances. Am J Psychiatry
Hales RE. Washington, DC, American Psychiatric Press, 1994, pp
9. Kraus MF: Neuropsychiatric sequelae: assessment and pharmaco-
20. Levin HS: Neurobehavioral sequelae of head injury, in Head Injury,
logic intervention, in Traumatic Brain Injury, Vol 14. Edited by
2nd Edition. Edited by Cooper PR. Baltimore, MD, Williams &
Marion DW. New York, Thieme Medicine Publishers, 1999, pp
21. Cripe LI: The neuropsychological assessment and management of
10. Kraus JF, Black MA, Hessol N, et al: The incidence of acute brain
closed head injury: general guidelines. Cognitive Rehabilitation
injury and serious impairment in a defined population. Am J Epi-
22. Wilson BA: Cognitive rehabilitation: how it is and how it might
11. Annegers JF, Grabow JD, Kurland CT, et al: The incidence, causes,
be. J Int Neuropsychol Soc 1997; 3:487–496
and secular trends in head injury in Olmstead County, Minnesota:
23. Karli DC, Burke TD, Kim HJ, et al: Effects of dopaminergic com-
1965–1974. Neurology 1980; 30:912–919
bination therapy for frontal lobe dysfunction in traumatic brain in-
12. Auerbach SH: The pathophysiology of traumatic brain injury, in
jury rehabilitation. Brain Inj 1999; 13:63–68
Physical Medicine and Rehabilitation: State of the Art Review,
24. Van Reekum R, Bayley M, Garner S, et al: N-of-1 study: amanta-
Traumatic Brain Injury, Vol 3. Edited by Horn IJ, Cope DN. Phila-
dine for the amotivational syndrome in a patient with TBI. Brain
delphia, PA, Hanley and Belfas, 1989, pp 1–11
25. Bleiberg J, Garmoe W, Cederquist J, et al: Effects of dexedrine on
49. Preston GC, Ward CE, Broks P, et al: Effects of lorazepam on
performance consistency following brain injury. Brain Inj 1993;
memory attention and sedation in attention by Ro15-1788. Psycho-
26. Kraus MF, Maki P: The combined use of amantadine and L-dopa/
50. Feeney DM, Gonzalez A, Law WA: Amphetamine, haloperidol,
carbidopa in the treatment of chronic brain injury. Brain Inj 1997;
and experience interact to affect rate of recovery after motor cortex
27. Taverni JP, Seligei G, Lichtman SW: Donepezil-mediated memory
51. Davison K, Bagley CK: Schizophrenia-like psychosis associated
improvement in traumatic brain injury during post-acute rehabili-
with organic disorder of the CNS. Br J Psychiatry 1969;
28. Goldberg E, Gerstman LJ, Mattis S, et al: Effects of cholinergic
52. Nasrallah HA, Fowler RC, Judd LL: Schizophrenia-like illness fol-
treatment on posttraumatic anterograde amnesia. Arch Neurol
lowing head injury. Psychosomatics 1981; 22:359–361
53. Brown G, Chadwick O, Shaffer D, et al: A prospective study of
29. Meyer A: The anatomical facts and clinical varieties of traumatic
children with head injuries: psychiatric sequelae. Psychol Med
insanity. Am J Insanity 1904; 60:373–441
30. Fedoroff JP, Starkstein SE, Forrester AW, et al: Depression in pa-
54. Thompsen C: Late outcome of very severe blunt head trauma: a
tients with traumatic brain injury. Am J Psychiatry 1992; 149:918–
10–15-year follow-up. J Neurol Neurosurg Psychiatry 1984;
31. Jorge RE, Robinson RG, Arndt SV, et al: Comparison between
55. Levine DN, Finkelstein S: Delayed psychosis after right temporal–
acute and delayed-onset depression following traumatic brain in-
parietal stroke or trauma: relation to epilepsy. Neurology 1982;
32. Hinkeldy NS, Corrigan JD: The structure of head-injured patients’
56. Lishman WA: Brain damage in relation to psychiatric disability
neurobehavioral complaints: preliminary studies. Brain Inj 1990;
after head injury. Br J Psychiatry 1968; 114:373–410
57. Feeney DM, Sutton RL: Pharmacotherapy for recovery of function
33. Van Zomeran AH, van den Burg W: Residual complaints of patients
after brain injury. Crit Rev Neurobiol 1997; 3:135–197
two years after severe head injury. J Neurol Neurosurg Psychiatry
58. Kant R, Duffy JD, Pivovarnik A: The prevalence of apathy follow-
ing head injury. Brain Inj 1988; 12:87–92
34. Starksein SE, Robinson RG, Price TR: Comparison of cortical and
59. Duffy JD, Campbell JJ: The regional prefrontal syndromes: a theo-
subcortical lesions in the production of poststroke mood disorders.
retical and clinical overview. J Neuropsychiatry Clin Neurosci
35. Bessette RF, Peterson LG: Fluoxetine and organic mood syndrome.
60. Gualtieri CT: Neuropsychiatry and Behavioral Pharmacology. New
36. Kraus MF: Neuropsychiatric sequelae of stroke and traumatic brain
61. Gerring JP: Psychiatric sequelae of severe closed head injury. Pe-
injury: the role of psychostimulants. Int J Psychiatry Med 1995;
62. Campbell JJ, Duffy JD, Salloway SP: Treatment strategies for pa-
37. Gualtieri CT, Evans RW: Stimulant treatment for the neurobehav-
tients with dysexecutive syndromes. J Neuropsychiatry Clin Neu-
ioral sequelae of TBI. Brain Inj 1988; 2:273–290
38. Ruedrich SL, Chu CC, Moore SL: ECT for major depression in a
63. Sohlberg KM, Mateer CA: Training use of compensatory memory
patient with acute brain trauma. Am J Psychiatry 1983; 140:928–
books: a three-stage behavioral approach. J Clin Exp Neuropsychol
39. Jorge RE, Robinson RG, Starksein SE, et al: Secondary mania fol-
64. Epstein NB, Bishop DS: Problem-centered systems therapy of the
lowing traumatic brain injury. Am J Psychiatry 1993; 150:916–921
family, in Handbook of Family Therapy. Edited by Gurman A,
40. Stuart JW, Hemsath RN: Bipolar illness following TBI treatment
Kniskern D. New York, Brunner/Mazel, 1981, pp 444–482
with lithium and carbamazepine. J Clin Psychiatry 1988; 49:74–75
65. Silver JM, Yudofsky SC: Psychopharmacology, in Neuropsychiatry
41. Robinson RG, Boston JD, Starkstein SE, et al: Comparison of ma-
of Traumatic Brain Injury. Edited by Silver JM, Yudofsky SC,
nia and depression after brain injury: causal factors. Am J Psychi-
Hales RE. Washington, DC, American Psychiatric Press, 1994, pp
42. Klonoff H: Head injuries in children: predisposing factors, accident
66. Evans RW: The post-concussion syndrome and the sequelae of mild
conditions, accident proneness, and sequelae. Am J Public Health
head injury. Neurol Clin 1992; 10:815–847
67. Levin HS, Mattis S, Ruff RM, et al: Neurobehavioral outcome fol-
43. Lewis A: Discussion on differential diagnosis and treatment of
lowing minor head injury: a three-center study. J Neurosurg 1987;
post-concussional states. Proceedings of the Royal Society of Med-
68. Rutherford WH, Merrett JD, McDonald JR: Symptoms at one year
44. Lewis L, Rosenberg SJ: Psychoanalytic psychotherapy with brain-
following concussion from minor head injuries. Brain Inj 1978;
injured adult psychiatric patients. J Nerv Ment Dis 1990; 178:69–
69. McLean A, Temkin NR, Dikmen S, et al: The behavioral sequelae
45. Paul SM: Anxiety and depression: a common neurobiological sub-
of head injury. J Clin Neuropsychol 1983; 5:361–376
strate. J Clin Psychiatry 1988; 49(suppl):13–16
70. Langfitt TW, Obrist WD, Alavi A, et al: Computerized tomography
46. Jorge RE, Robinson RG, Starkstein SE, et al: Depression and anxi-
magnetic resonance imaging and positron emission tomography in
ety following TBI. J Neuropsychiatry Clin Neurosci 1993; 5:369–
the study of brain tumor. J Neurosurg 1988; 64:760–767
71. Gray BG, Ichise M, Chung DG, et al: Technitium 99m HMPAO
47. Tennant FS: Naltrexone treatment for PCS. Am J Psychiatry 1987;
SPECT in evaluation of a patient with a remote history of TBI: a
comparison with x-ray computed tomography. J Nucl Med 1992;
48. Gualiteri CT: Buspirone: neuropsychiatric effects. J Head Trauma
72. Evans RW, Gualtieri CT, Patterson DR: Treatment of chronic closed
head injury with psychostimulant drugs: a controlled case study of
79. Mattes JA: Comparative effectiveness of carbamazepine and pro-
an appropriate evaluation procedure. J Nerv Ment Dis 1987;
pranolol for rage outburst. J Neuropsychiatry Clin Neurosci 1990;
73. Schwab RS, England AC, Postkanza DC, et al: Amantadine in the
80. Giakas WJ, Seibyl JP, Mazure CM: Valproate in the treatment of
treatment of Parkinson’s disease. JAMA 1969; 208:1168–1170
temper outburst (letter). J Clin Psychiatry 1990; 51:525
74. Nickels JL, Schneider WN, Dombovy ML, et al: Clinical use of
81. Timble MR: Anticonvulsant drug and cognitive function: a review
amantadine in brain injury rehabilitation. Brain Inj 1994; 8:709–
of literature. Epilepsia 1987; 28:S37–S45
82. Sokol MS, Campbell M: Novel psychoactive agents in the treat-
75. Lal S, Merbitz CP, Gripp JC: Modification of function in a head
ment of developmental disorders, in Psychopharmacology of the
injury patient with Sinemet. Brain Inj 1988; 2:225–233
Developmental Disabilities. Edited by Aman MG, Sigh NN. New
76. Dobkin BH, Hanlan R: Dopamine against treatment of anterograde
York, Springer-Verlag, 1988, pp 147–167
amnesia from a mediobasal forebrain injury. Ann Neurol 1993;
83. Childs A: Naltrexone in organic bulimia: a preliminary report.
77. Saran AS: Depression after minor closed head injury: role of dexa-
84. Levine AM: Buspirone and agitation in head injury. Brain Inj 1988;
methasone suppression test and antidepressants. J Clin Psychiatry
85. Yudofsky SC, Silver JM, Schneider SE: Pharmacological treatment
78. Nirenberg AA, Addler LA, Peselow E, et al: Trazodone for anti-
of aggression. Psychiatric Annals 1987; 17:397–407
depressant and related insomnia. Am J Psychiatry 1994; 151:1069–1072
Klinische Leitlinien zur Behandlung von Schulkindern mit einer Auf- merksamkeitsdefizit/ Hyperaktivitätsstörung (ADHS) Gekürzte Zusammenfassung von „Clinical Practice Guideline:Treatment of the School-Aged Child with ADHD“ der Ameri- can Academy of Pediatrics, PEDIATRICS Vol. 108 No 4, Oct. 2001, S 1033ff Dr. med. M. Ryffel Die vorliegenden Leitlinien sind für Erstversorger, d.h. in d
TRIMIDINETM POWDER Australia: FOR THE TREATMENT OF INFECTIONS DUE TO ORGANISMS SUSCEPTIBLE TO THE COMBINATION OF SULFADIMIDINE AND TRIMETHOPRIM IN HORSES, CALVES, PIGS AND POULTRY. New Zealand: FOR THE TREATMENT OF INFECTIONS DUE TO ORGANISMS SUSCEPTIBLE TO THE COMBINATION OF SULFADIMIDINE AND TRIMETHOPRIM IN HORSES. PRESENTATION: Powder. ACTIVE CONSTITUENTS: Each gra